Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced ...

A new review was published in Volume 18 of Aging on May 30, 2026, titled "The love and hate relationship between cellular ...

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.

Cambrian Bio, a clinical-stage drug development company with pipeline therapies targeting critical metabolic pathways that ...

The protein mTOR becomes excessively active in cancer cells, driving tumor growth and metastasis. The molecular mechanisms ...

Terpenoids represent the most diverse class of specialized metabolites in plants, yet they originate from just two simple precursors—isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Lizzy leads STAT’s coverage of the FDA. Her ...

The new pathway aligns with health leaders' stated goal of reducing red tape for cell and gene therapies, but contrasts with the surprising recent rejections of ...

Many of us will recognize being in a situation where it’s really hard to get started on a task—whether it’s making a difficult phone call or preparing a presentation that’s stressful just to think ...

Researchers from Miguel Hernández University of Elche (UMH) in Spain have identified an effective strategy to reduce structural liver damage and improve hepatic vascular function in cirrhosis. The ...